Search
Pittsburgh, PA Paid Clinical Trials
A listing of 1194 clinical trials in Pittsburgh, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
877 - 888 of 1194
There are currently 1194 clinical trials in Pittsburgh, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pittsburgh, University of Pittsburgh Medical Center, Alleghany General Hospital and Children's Hospital of Pittsburgh UPMC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Cardiac Implantable Electronic Device (CIED) Research Study
Recruiting
The study is designed to collect data on Cardiovascular Implantable Electronic Device (CIED) information, implant procedure details, and/or patient characteristics to support development of future CIED products and procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Arrhythmias, Cardiac, Bradycardia, Tachycardia
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Recruiting
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
01/10/2025
Locations: AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Study of INBRX-109 in Conventional Chondrosarcoma
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Conventional Chondrosarcoma
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
Recruiting
The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: UPMC Children's Hospital, Pittsburgh, Pennsylvania
Conditions: Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania +5 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Recruiting
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
01/08/2025
Locations: Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Gestational Diabetes
Adult Patient Outcomes After Spine Surgery with Fibergraft BG Putty/Viper Prime
Recruiting
The Viper Prime/Expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have compared the use of Viper prime/Expedium spine system in minimally invasive and open surgeries, t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Spondylolisthesis, Lumbar Region, Spinal Trauma with Neurological Deficit, Degeneration of Lumbar Intervertebral Disc
Data Collection Study of Patients with Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT with RIC
Recruiting
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
Gender:
ALL
Ages:
Between 2 months and 60 years
Trial Updated:
01/07/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Pancreatic Quantitative Sensory Testing (P-QST) to Predict Treatment Response for Pain in Chronic Pancreatitis
Recruiting
Abdominal pain in chronic pancreatitis (CP) affects up to 90% of patients during the course of their disease, and response to currently available therapies is suboptimal and unpredictable. The proposed clinical trial will evaluate the predictive capability of Pancreatic Quantitative Sensory Testing (P-QST) - a novel assessment of neurosensory phenotyping- for improvement in pain in patients with CP who are undergoing medically-indicated invasive treatment with endoscopic therapy or surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Chronic Pancreatitis, Chronic Pain
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Recruiting
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/07/2025
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD
QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing
Recruiting
Quantitative Sensory Testing (QST) is a novel investigative technique used in other pain conditions to evaluate patterns of chronic pain, and in this study will be used to elucidate pain patterns in patients with Chronic Pancreatitis (CP). QST uses a specific series of standardized stimulations to map the pain system. QST has the potential to change and improve the treatment paradigm for patients with CP and may eventually be able to predict response to invasive CP therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Chronic Pancreatitis, Chronic Pain
Autologous Stem Cell Transplantation for Crohn's Disease
Recruiting
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
Gender:
ALL
Ages:
Between 10 years and 60 years
Trial Updated:
01/07/2025
Locations: UPMC Prebyterian- Adult Gastroenterology, Pittsburgh, Pennsylvania +1 locations
Conditions: Crohn's Disease
877 - 888 of 1194